Effects of 21-day Purification Program on Healthy Adults

Inclusion Criteria: * Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee. * Willingness to comply with study protocol for 58 days * Willingness to come and provide samples on all 4 study visits * No allergy to any study products (a complete list of what supplements will assist is provided below)) * Subject is \>18 years of age * Subject is a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit, and is not actively planning a pregnancy * If on a chronic medication (that does not result in exclusion), subject has been on stable dose for at least two months prior to screening visit * Subject has at least two weeks wash out period between completion of a previous research study that required ingestion of any study food or drug and their start in the current study * Willingness to stay compliant for 22 days and not participate in another research study Exclusion Criteria: * Prohibited Medications, Supplements or Herbal Products * Subjects who are experiencing any adverse events due to any nutraceutical, OTC, or pharmaceutical or investigational products * Celiac and other gastrointestinal health concerns * Subjects may not receive any other investigational products not part of normal clinical care * Lipid lowering drugs in the preceding 4 weeks and for duration of study \[examples- statins, cholesterol absorption inhibitors like Ezetimibe (Zetia), PCSK9 inhibitors like Alirocumab (Praluent), Evolocumab (Repatha) etc.\] * The use of anticoagulant medications in the preceding 4 weeks and for duration of study \[Examples: apixaban (Eliquis), betrixaban (Bevyxxa), edoxaban (Savaysa), and rivaroxaban (Xarelto) etc.\] * Pregnant and nursing women are excluded from participation and women of childbearing age expecting to be pregnant soon will be excluded from the study * Subjects with untreated endocrine, neurological, or infectious disease * Subjects with the diagnosis of HIV disease or AIDS * Significant liver or kidney disease (recent or ongoing hepatitis, cirrhosis, glomerulonephritis, dialysis treatment) * Rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, polymyositis, scleroderma, polymyalgia rheumatic, temporal arteritis or Reiter's Syndrome * Psoriasis, Deep vein thrombosis or pulmonary embolus (blood clot to lungs) * History of cancer * Serious medical illness like high TG levels \>150 mg/DL for example * Substance Use - Use of ethanol within 24 hours of the evaluation visits (all 4 visits) * Any other sound medical, psychiatric and/or social reason as determined by the PI * Co-enrollment in other studies is restricted. Study staff should be notified of co-enrollment as it may require the approval of the investigator